{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:44Z","timestamp":1790610824323,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to analyze the adverse drug events (ADEs) associated with tolvaptan in the Food and Drug Administration Adverse Event Reporting System database from the fourth quarter of 2009 to the second quarter of 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After standardizing the data, various signal detection techniques, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network, and Multi-Item Gamma Poisson Shrinker, were employed for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 7,486 ADE reports where tolvaptan was the primary suspected drug, a total of 196 preferred terms were identified, spanning 24 different system organ classes. Specifically, hepatobiliary disorders, renal and urinary disorders, and metabolic and nutritional disorders were found to be characteristic adverse reactions associated with tolvaptan. Additionally, uncommon but notable ADE signals were observed, such as renal cyst rupture, renal cyst infection, polycystic liver disease, and renal cyst hemorrhage. These several ADEs have not been referred to in the previous literature. Notably, strong ADE signals were detected for decreased urine osmolality [n = 5, ROR 149.74, PRR 149.7, IC (Information Component) 7.13, EBGM (Empirical Bayes Geometric Mean) 139.79], osmotic demyelination syndrome (n = 38, ROR 128.47, PRR 128.25, IC 6.92, EBGM 120.91), and pulmonary-related tumors such as bronchial metastatic carcinoma, bronchial carcinoma, metastatic small cell lung carcinoma, and small cell lung carcinoma. In the concomitant medication analysis of 7,486 suspected adverse drug reaction reports related to tolvaptan, the top three drugs most commonly used in combination with tolvaptan were furosemide, spironolactone, and amlodipine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While tolvaptan provides therapeutic benefits, it poses a risk of significant adverse reactions. Clinicians should closely monitor the occurrence of events related to hepatobiliary disorders, renal and urinary disorders, metabolic and nutritional disorders, as well as benign, malignant, and indeterminate tumors during its clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1509310","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:13:48Z","timestamp":1736385228000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Peiyang","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.ekir.2021.06.028","article-title":"Pulmonary embolism in a patient with ADPKD treated with tolvaptan: from the clinical experience to the analysis of the Food and drug administration adverse event reporting system registry","volume":"6","author":"Aiello","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials","volume":"81","author":"Alpers","year":"2023","journal-title":"Am. J. kidney Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1517\/14656566.2011.567267","article-title":"Tolvaptan for the treatment of heart failure: a review of the literature","volume":"12","author":"Ambrosy","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1309657","DOI":"10.3389\/fendo.2023.1309657","article-title":"Case report: twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD","volume":"14","author":"Arecco","year":"2024","journal-title":"Front. Endocrinol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40265-019-1056-1","article-title":"Tolvaptan: a review in autosomal dominant polycystic kidney disease","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.5301\/tj.5000249","article-title":"Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH","volume":"101","author":"Bordi","year":"2015","journal-title":"Tumori"},{"key":"B8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"B10","first-page":"99","article-title":"Alterations in renal tubular sodium and water transport in polycystic kidney disease","volume":"3","author":"D'Angelo","year":"1975","journal-title":"Clin. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am. Statistician"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s40620-024-02053-z","article-title":"Evaluating physician confidence and barriers in prescribing tolvaptan for ADPKD management: a comprehensive online survey study","volume":"37","author":"Ebrahimi","year":"2024","journal-title":"J. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1007\/s12325-021-01947-9","article-title":"Using tolvaptan to treat hyponatremia: results from a post-authorization pharmacovigilance study","volume":"38","author":"Estilo","year":"2021","journal-title":"Adv. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12325-019-01201-3","article-title":"Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature","volume":"37","author":"Farkouh","year":"2020","journal-title":"Adv. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1517\/14740338.4.5.929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben","year":"2005","journal-title":"Expert Opin. drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e15261","DOI":"10.1097\/MD.0000000000015261","article-title":"Acute parkinsonism as an unexpected consequence of pituitary adenoma resection: a case report","volume":"98","author":"Ho","year":"2019","journal-title":"Medicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ehf2.12738","article-title":"Renoprotective effect of tolvaptan in patients with new-onset acute heart failure","volume":"7","author":"Kin","year":"2020","journal-title":"Esc. heart Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2169\/internalmedicine.1697-18","article-title":"Hemodynamic and hormonal effects of tolvaptan for heart failure","volume":"58","author":"Kiuchi","year":"2019","journal-title":"Intern. Med. Tokyo, Jpn."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.3390\/jcm12175483","article-title":"Safety and efficacy of vaptans in the treatment of hyponatremia from syndrome of inappropriate antidiuretic hormone secretion (SIADH): a systematic review and meta-analysis","volume":"12","author":"Krisanapan","year":"2023","journal-title":"J. Clin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"111419","DOI":"10.1016\/j.mce.2021.111419","article-title":"Low sodium and tolvaptan have opposite effects in human small cell lung cancer cells","volume":"537","author":"Marroncini","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"8402","DOI":"10.3390\/ijms25158402","article-title":"The vasopressin receptor antagonist tolvaptan counteracts tumor growth in a murine xenograft model of small cell lung cancer","volume":"25","author":"Naldi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.21037\/tcr-20-2123","article-title":"The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases","volume":"10","author":"Ren","year":"2021","journal-title":"Transl. cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/toxsci\/kfv231","article-title":"Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites: contributing factors to drug-induced liver injury?","volume":"149","author":"Slizgi","year":"2016","journal-title":"Toxicol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000481995","article-title":"Effects of tolvaptan addition to furosemide in normo- and hyponatremia patients with heart failure and chronic kidney disease stages g3b-5: a subanalysis of the K-STAR study","volume":"46","author":"Tominaga","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"25943","DOI":"10.1038\/s41598-024-77052-y","article-title":"Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases","volume":"14","author":"Uno","year":"2024","journal-title":"Sci. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","article-title":"Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors","volume":"155","author":"Woodhead","year":"2017","journal-title":"Toxicol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"19360","DOI":"10.1038\/s41598-021-98173-8","article-title":"Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan","volume":"11","author":"Yamazaki","year":"2021","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart failure society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1509310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:13:50Z","timestamp":1736385230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1509310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":36,"alternative-id":["10.3389\/fphar.2024.1509310"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1509310","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"1509310"}}